CNP 520

Drug Profile

CNP 520

Alternative Names: AMG 520; CNP520

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Amgen; Novartis
  • Class Antidementias; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 03 Aug 2017 Phase-II/III clinical trials in Alzheimer's disease in Puerto Rico, Spain (PO) (NCT03131453) (EudraCT2016-002976-28)
  • 03 Aug 2017 Novartis initiates enrolment in the Generation S2 phase-II/III trial for Alzheimer's disease in USA (PO) (NCT03131453) (EudraCT2016-002976-28)
  • 16 Jul 2017 Safety, tolerability, pharmacokinetic and pharmacodynamic data from a phase IIa trial in Alzheimer’s disease presented at the Alzheimer’s Association International Conference 2017 (AAIC 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top